Richard Stanley Bedlack
Professor of Neurology
Overview
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Selected Grants
Healy ALS Platform study - Regimen E ¿ Trehalose TO#10 awarded by Massachusetts General Hospital (Principal Investigator). 2021 to 2023
Healey ALS Platform Trial Open Label Extension Zilucoplan awarded by Massachusetts General Hospital (Principal Investigator). 2020 to 2023
A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS awarded by MediciNova, INC. (Principal Investigator). 2020 to 2022
Potential Role of the Gut Microbiome in ALS Progression and Reversals awarded by Augie's Quest to Cure ALS (Principal Investigator). 2021 to 2022
Potential Role of the Gut Microbiome in ALS Progression awarded by Martha Olson-Fernandez Foundation (Principal Investigator). 2021 to 2022
ALS Telemedicine awarded by Amyotrophic Lateral Sclerosis Association (Principal Investigator). 2021 to 2022
The Duke ALS Association Certified Center awarded by Amyotrophic Lateral Sclerosis Association (Principal Investigator). 2018 to 2022
I AM ALS awarded by Massachusetts General Hospital (Principal Investigator). 2021
Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami (Principal Investigator). 2019 to 2021
EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002 awarded by Orion Corporation (Principal Investigator). 2019 to 2021
Pages
Mehta, Paul, et al. “Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism.” Journal of Medical Internet Research, vol. 23, no. 12, Dec. 2021, p. e28021. Epmc, doi:10.2196/28021. Full Text
Bedlack, R. S., et al. “Accessing Investigational Products Outside of a Trial: Considerations for Neuromuscular Providers.” Current Treatment Options in Neurology, vol. 23, no. 12, Dec. 2021. Scopus, doi:10.1007/s11940-021-00697-x. Full Text
Oskarsson, Björn, et al. “MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.” Neurodegenerative Disease Management, vol. 11, no. 6, Dec. 2021, pp. 431–43. Epmc, doi:10.2217/nmt-2021-0042. Full Text
Bedlack, Richard, et al. “ALSUntangled 59: Tamoxifen.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, vol. 22, no. 7–8, Nov. 2021, pp. 595–98. Epmc, doi:10.1080/21678421.2021.1876731. Full Text
Bedlack, Richard, et al. “ALSUntangled #63: ketogenic diets.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, Oct. 2021, pp. 1–5. Epmc, doi:10.1080/21678421.2021.1990346. Full Text
Galea, Marinella D., et al. “Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19.” Muscle & Nerve, vol. 64, no. 4, Oct. 2021, pp. E18–20. Epmc, doi:10.1002/mus.27373. Full Text
Cudkowicz, Merit, et al. “Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.” The Lancet. Neurology, vol. 20, no. 10, Oct. 2021, pp. 821–31. Epmc, doi:10.1016/s1474-4422(21)00242-8. Full Text
Choi, Philip J., et al. “Continuing Non-Invasive Ventilation During Amyotrophic Lateral Sclerosis-Related Hospice Care Is Medically, Administratively, and Financially Feasible.” The American Journal of Hospice & Palliative Care, vol. 38, no. 10, Oct. 2021, pp. 1238–41. Epmc, doi:10.1177/1049909120982291. Full Text
Li, Xiaoyan, and Richard Bedlack. “COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis.” Muscle & Nerve, vol. 64, no. 3, Sept. 2021, pp. E13–15. Epmc, doi:10.1002/mus.27351. Full Text
ALSUNTANGLED GROUP, Paul. “ALSUntangled #61: melatonin.” Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, May 2021, pp. 1–4. Epmc, doi:10.1080/21678421.2021.1927103. Full Text
Pages
Bedlack, Richard S., et al. “Scrutinizing enrollment in ALS clinical trials: Room for improvement?” Neurology, vol. 70, no. 11, LIPPINCOTT WILLIAMS & WILKINS, 2008, pp. A344–A344.
Bedlack, R. S., and S. Torres. “Multifocal motor neuropathy with upper motor neuron signs.” Muscle & Nerve, vol. 34, no. 4, JOHN WILEY & SONS INC, 2006, pp. 514–514.
Bedlack, R. S., et al. “Apolipoprotein E genotype is a risk factor for diabetic neuropathy.” Annals of Neurology, vol. 52, no. 6, WILEY-LISS, 2002, pp. 866–866.
Gross, E., et al. “Fluorescent imaging of membrane potential components.” Analytical Use of Fluorescent Probes in Oncology, edited by E. Kohen and J. G. Hirschberg, vol. 286, PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996, pp. 249–56.
BEDLACK, R. S., et al. “ENDOGENOUS ELECTRIC-FIELDS WITHIN THE NEURONAL PLASMALEMMA - NONUNIFORMITIES SUGGESTING DIFFERENTIAL VOLTAGE-DEPENDENCE.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.
GROSS, E., et al. “DUAL-WAVELENGTH RATIOMETRIC FLUORESCENCE MEASUREMENT OF THE MEMBRANE DIPOLE POTENTIAL.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.
BEDLACK, R. S., et al. “ELECTRIC FIELD-BIASED N1E-115 GROWTH CONE FILOPODIAL PROTRUSIONS ARE INHIBITED BY VERAPAMIL.” Biophysical Journal, vol. 64, no. 2, BIOPHYSICAL SOCIETY, 1993, pp. A101–A101.